Hormone Resistance

Area of Science:

• Oncology
• Endocrinology
• Genetics

Background:

• Hormone therapy is crucial for hormone receptor-positive breast cancer, yet resistance remains a significant clinical challenge.
• Mechanisms of resistance involve estrogen receptor alpha (ERα) alterations, co-factor changes, and activation of growth pathways like PI3K/Akt/mTOR and cell cycle pathways.
• Emerging therapies include selective estrogen receptor down-regulators, CDK 4/6 inhibitors, PI3K/AKT/mTOR inhibitors, and HDAC inhibitors.

Purpose of the Study:

• To investigate endocrine resistance in young breast cancer patients (under 35 years old).
• To identify specific mechanisms of endocrine resistance in this demographic.
• To explore potential therapeutic strategies and clinical trial designs for overcoming resistance in young women.

Main Methods:

• Analysis of single-center data and Korean Breast Cancer Registry data.
• Gene expression profiling in hormone receptor-positive breast cancer in very young patients (<35) compared to premenopausal women in their forties.
• Review of existing clinical studies and trials investigating endocrine resistance mechanisms and novel agents.

Main Results:

• Age under 35 is identified as a poor prognostic factor for hormone receptor-positive breast cancer.
• Younger women (<35) exhibit reduced response to anti-hormonal therapy.
• Increased expression of cell cycle-related genes is observed in very young patients (<35) compared to older premenopausal women.

Conclusions:

• Endocrine resistance in young women (<35) with hormone receptor-positive breast cancer presents unique challenges and requires further investigation.
• The precise mechanisms of recurrence after endocrine treatment, especially in younger populations, are not fully understood.
• Developing targeted drug combinations and tailored clinical trials is essential to overcome endocrine resistance in this vulnerable group.